Publications by authors named "Maricruz Cassou Martinez"
Background: COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City.
View Article and Find Full Text PDFCase: We present the case of a woman who, during the neonatal period, presented salt-losing adrenal insufficiency associated with 46 XY gonadal dysgenesis. The genetic study found a steroidogenic acute regulatory protein (StAR) mutation.
Conclusion: Mutations in StAR result in a nonfunctional protein, which clinically translates into congenital adrenal hyperplasia and, in the case of patients with 46 XY karyotype, is accompanied by gonadal dysgenesis characterized by androgen deficiency, without alterations in anti-Müllerian hormone.
Article Synopsis
- BE-COPD patients, exposed to biomass, may be more vulnerable to COVID-19 than TE-COPD patients, who are affected by tobacco smoke.
- The study found an 11% prevalence of COVID-19 in both groups, with no significant differences in infection rates or risk factors like housing or knowledge about COVID-19.
- Poor socioeconomic status was noted in the BE-COPD group, and around 40% of patients had inadequate risk perception and adherence to health guidelines during the pandemic.